Novo Nordisk A/S
NVO
$68.17
-$0.03-0.04%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.59B | 42.09B | 39.35B | 37.42B | 35.53B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.59B | 42.09B | 39.35B | 37.42B | 35.53B |
| Cost of Revenue | 6.69B | 6.32B | 5.97B | 5.73B | 5.39B |
| Gross Profit | 36.90B | 35.77B | 33.38B | 31.69B | 30.14B |
| SG&A Expenses | 9.94B | 9.76B | 9.55B | 9.16B | 9.09B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -151.29M | -66.61M | -5.46M | -34.65M | 25.98M |
| Total Operating Expenses | 22.48B | 21.82B | 21.00B | 20.12B | 19.31B |
| Operating Income | 21.11B | 20.27B | 18.36B | 17.30B | 16.23B |
| Income Before Tax | 19.03B | 18.45B | 17.36B | 16.39B | 16.28B |
| Income Tax Expenses | 3.98B | 3.80B | 3.57B | 3.34B | 3.29B |
| Earnings from Continuing Operations | 15.05K | 14.65K | 13.79K | 13.05K | 12.99K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.05B | 14.65B | 13.79B | 13.05B | 12.99B |
| EBIT | 21.11B | 20.27B | 18.36B | 17.30B | 16.23B |
| EBITDA | 22.66B | 21.60B | 19.65B | 18.65B | 17.44B |
| EPS Basic | 3.38 | 3.29 | 3.09 | 2.92 | 2.91 |
| Normalized Basic EPS | 2.91 | 2.82 | 2.59 | 2.45 | 2.32 |
| EPS Diluted | 3.38 | 3.28 | 3.09 | 2.91 | 2.90 |
| Normalized Diluted EPS | 2.90 | 2.82 | 2.58 | 2.45 | 2.31 |
| Average Basic Shares Outstanding | 17.80B | 17.82B | 17.83B | 17.86B | 17.89B |
| Average Diluted Shares Outstanding | 17.83B | 17.85B | 17.87B | 17.90B | 17.94B |
| Dividend Per Share | 1.63 | 1.63 | 1.43 | 1.43 | 1.36 |
| Payout Ratio | 48.33% | 44.06% | 46.82% | 46.91% | 47.10% |